"Injections, Subcutaneous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.
| Descriptor ID |
D007279
|
| MeSH Number(s) |
E02.319.267.530.620
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Injections, Subcutaneous".
Below are MeSH descriptors whose meaning is more specific than "Injections, Subcutaneous".
This graph shows the total number of publications written about "Injections, Subcutaneous" by people in this website by year, and whether "Injections, Subcutaneous" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2014 | 0 | 3 | 3 |
| 2016 | 0 | 2 | 2 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 2 | 2 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Injections, Subcutaneous" by people in Profiles.
-
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. N Engl J Med. 2023 Aug 31; 389(9):783-794.
-
The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021 02 13; 397(10274):630-640.
-
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020 04 16; 382(16):1507-1519.
-
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020 04 16; 382(16):1520-1530.
-
Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. Clin Cardiol. 2018 Oct; 41(10):1328-1335.
-
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018 08 30; 379(9):811-822.
-
Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 08 31; 377(9):809-818.
-
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. N Engl J Med. 2017 04 20; 376(16):1527-1539.
-
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016 May 26; 374(21):2054-64.
-
Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies. Clin Infect Dis. 2016 May 01; 62(9):1178-1185.